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Abstract AMP-activated protein kinase (AMPK) is known to
be activated by phosphorylation on Thr172 in response to an
increased AMP/ATP ratio. We report here that such an
activation indeed occurred in anaerobic rat hearts and that
it was antagonized (40^50%) when the hearts were pre-treated
with 100 nM insulin. The effect of insulin (1) was blocked by
wortmannin, an inhibitor of phosphatidylinositol-3-kinase; (2)
only occurred when insulin was added before anoxia, suggesting a
hierarchical control ; (3) resulted in a decreased phosphorylation
state of Thr172 in AMPK and (4) was unrelated to changes in
the AMP/ATP ratio. This is the first demonstration that AMPK
activity could be changed without a detectable change in the
AMP/ATP ratio of the cardiac cell. ß 2001 Federation of
European Biochemical Societies. Published by Elsevier Science
B.V. All rights reserved.
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1. Introduction
AMP-activated protein kinase (AMPK) is a well-conserved
eukaryotic protein kinase that senses the energy state of the
cell. It is activated under anaerobic conditions and acts as a
metabolic master switch [1]. AMPK is a heterotrimeric protein
composed of a catalytic subunit (K) and two regulatory sub-
units (L and Q). Isoforms of all three subunits are known.
Their subcellular location di¡ers but their respective roles re-
main unclear [2,3]. In the heart, the K2 isoform of the catalytic
subunit is more abundant than K1 [4].
The control of AMPK activity is complex. It involves allo-
steric stimulation by AMP as well as phosphorylation [1].
AMP allosterically stimulates both AMPK and AMPK-kinase
(AMPKK), the upstream kinase. In addition, AMP promotes
AMPK phosphorylation by AMPKK and prevents its de-
phosphorylation by protein phosphatase 2C. Activation of
AMPK results from phosphorylation of Thr172 in the activa-
tion loop of the catalytic K-subunit, although other phosphor-
ylation sites have been reported [5]. ATP is a competitive
inhibitor with regards to AMP with, however, a more than
10-fold lower a⁄nity [1]. Therefore, in normoxic hearts, ATP
(5^10 mM) antagonizes the e¡ect of the low AMP concentra-
tion (0.1^0.2 mM) and keeps AMPK mainly in the inactive
dephosphorylated form. By contrast, when the energy state of
the cell collapses as in ischemic or anoxic hearts, the AMP/
ATP ratio increases and activates AMPK 5^10-fold [6,7].
AMPK is also activated allosterically by a decreased phos-
phocreatine/creatine (PCr/Cr) ratio in muscle [8]. This reinfor-
ces the activity-dependence of AMPK on the energy state of
the cell.
In hearts submitted to anaerobic conditions, AMPK acti-
vation participates in the stimulation of glycolysis by enhanc-
ing the recruitment of GLUT4 [9] to the plasma membrane
and by activating 6-phosphofructo-2-kinase [7]. This enzyme
synthesizes fructose 2,6-bisphosphate, a potent positive allo-
steric e¡ector of 6-phosphofructo-1-kinase, a key glycolytic
enzyme. AMPK also inactivates acetyl-CoA carboxylase
(ACC) [10]. ACC inactivation might persist during reperfu-
sion following an ischemic episode, and so contributes to a
stimulation of fatty acid oxidation during this period [11].
Indeed, ACC activity controls the concentration of malonyl-
CoA, which is a potent inhibitor of the entry of long-chain
fatty acids into mitochondria. Phosphorylation and activation
of malonyl-CoA decarboxylase, a recently discovered sub-
strate of AMPK, exerts the same overall e¡ect on fatty acid
metabolism [12]. In normoxic hearts, AMPK has been re-
ported to be inactivated by insulin [13,14]. This e¡ect was
proposed to mediate ACC activation and inhibition of fatty
acid oxidation by insulin. The mechanism involved in the
control of AMPK activity by insulin is unknown.
In this work, we studied the e¡ect of insulin to antagonize
AMPK activation in rat hearts submitted to ischemia or an-
oxia. Insulin was found to inactivate AMPK by decreasing the
phosphorylation state of Thr172 by a mechanism unrelated to
changes in the AMP/ATP and PCr/Cr ratios. This is the ¢rst
report that AMPK activity was changed without detectable
change in the AMP/ATP ratio of the cardiac cell.
2. Materials and methods
2.1. Perfusion protocol
Hearts from male Wistar rats (200^220 g body weight, anesthetized
with 50 mg/kg pentobarbital injected intraperitoneally) were perfused
[15] retrogradely at a constant pressure of 60 mm Hg with a Krebs
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Henseleit bicarbonate bu¡er containing 1.5 mM CaCl2 and 5 mM
glucose and in equilibrium with a 95% O2/5% CO2 gas phase, if not
otherwise stated. No-£ow ischemia was obtained by interrupting the
£ow. Anoxia was obtained by replacing O2 by N2 in the gas phase.
Hearts were freeze-clamped at the times indicated in the ¢gures.
2.2. AMPK activity and phosphorylation state
The frozen hearts were homogenized (Ultra-Turrax) at 0^4‡C in
5 (v/w) vol of lysis bu¡er (50 mM HEPES at pH 7.5, 50 mM KCl,
50 mM NaF, 5 mM sodium pyrophosphate, 1 mM EDTA, 1 mM
EGTA, 1 mM dithiothreitol, 5 mM L-glycerolphosphate, 100 nM
microcystin-LR, and protease inhibitors (4 Wg/ml leupeptin, 1 mM
benzamidine hydrochloride, 0.7 Wg/ml pepstatin, 0.2 WM phenylmeth-
ylsulfonyl £uoride and 0.4 Wg/ml trypsin inhibitor)) and the super-
natants (10 000Ug, 30 min) were stored at 380‡C [7]. AMPK activity
was assayed in the presence of 0.2 mM AMP in a 10% polyethylene
glycol 6000 fraction [7,16]. 1 unit of protein kinase activity corre-
sponds to the formation of 1 nmol of product per minute under the
assay conditions. AMPK phosphorylation state was determined by
immunoblotting (anti-phosphoThr172 AMPK antibody) after immu-
noprecipitation with anti-K1 and/or anti-K2 AMPK antibodies [17,18].
Proteins were measured by Coomassie blue staining with bovine se-
rum albumin as a standard.
2.3. Metabolites
AMP, ADP and ATP were measured in neutralized perchloric acid
extracts of the frozen hearts after their separation by high-perfor-
mance liquid chromatography (HPLC) [19]. PCr, Cr and lactate
were measured enzymatically in the same extracts, as in [20]. It should
be noted that adenine nucleotides and (P)Cr were measured in depro-
teinized extracts of whole tissue, and so any compartmentation was
not taken into account.
3. Results
AMPK activity was measured in hearts submitted to peri-
ods of no-£ow ischemia, ranging from 0 to 20 min (Fig. 1A).
The basal AMPK activity was low, as expected for normoxic
conditions. AMPK activity increased progressively during the
Fig. 1. E¡ect of insulin pre-treatment on AMPK activity (A), AMP/ATP (B) and PCr/Cr (C) ratios, and lactate accumulation (D) in rat hearts
submitted to no-£ow ischemia. A scheme of the experimental protocol and the times of sampling are given at the top of the ¢gure. After
15 min equilibration, the hearts were perfused for 5 min with insulin (100 nM) before ischemia was started. B: The inset represents the AMP/
ATP ratio during the ¢rst 10 min ischemia. The absolute values (Wmol/g wet tissue) ranged from 2.67 þ 0.16 to 0.43 þ 0.16 for ATP, from
0.90 þ 0.12 to 0.47 þ 0.07 for ADP, from 0.14 þ 0.02 to 1.26 þ 0.16 for AMP, from 4.94 þ 0.23 to 0.22 þ 0.08 for PCr and from 8.5 þ 0.5 to
3.76 þ 0.42 for Cr (control vs. 20 min ischemia, without insulin). D: Lactate content (Wmol/g wet tissue) was measured in hearts submitted to
10 min no-£ow ischemia. Open bars: control hearts; closed bars: insulin pre-treated hearts. The values are the means þ S.E.M. of four hearts.
*P6 0.05 indicates values that are statistically di¡erent from the corresponding values at the same perfusion times.
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ischemic episode to reach a 10-fold activation after 10 min.
The activation was transient and AMPK activity returned
towards basal values between 10 and 20 min. Pre-treatment
for 5 min with 100 nM insulin antagonized the activation of
AMPK during ischemia at 5 min and onwards. The inhibition
was maximal (40%) at 10 min ischemia.
Changes in AMPK activity are known to result from alter-
ations in AMP/ATP as well as PCr/Cr ratios. AMPK activa-
tion strictly correlated with changes in the AMP/ATP (Fig.
1B) and PCr/Cr (Fig. 1C) ratios during the ¢rst 10 min ische-
mia. One can calculate that, between 2 and 10 min ischemia,
AMPK activity doubled (Fig. 1A) for an increase in the AMP/
ATP ratio of about 0.3 (inset Fig. 1B). However, the relation-
ship between AMPK activity and AMP/ATP ratio did not
hold true for the last 10 min ischemia, when the AMP/ATP
ratio drastically increased (Fig. 1B), whereas AMPK activity
decreased (Fig. 1A). Importantly, insulin did not a¡ect the
AMP/ATP ratio at any time (Fig. 1B), although it did inhibit
AMPK activation (Fig. 1A). From the relationship between
changes in AMPK activity and changes in the AMP/ATP
ratio in ischemic hearts, one can calculate that the change in
AMPK activity brought about by insulin (400 mU/mg pro-
tein) should have corresponded to a change of about 0.2 in
the AMP/ATP ratio. Such an easily detectable change in the
AMP/ATP ratio was obviously not found. Moreover, insulin
was without e¡ect on the large decrease in the PCr/Cr ratio
observed after 2 min ischemia (Fig. 1C), and it did not modify
the glycolytic rate as indicated by lactate accumulation in the
ischemic hearts (Fig. 1D). This demonstrated that insulin
could change AMPK activity without a¡ecting the energy
state of the ischemic hearts.
The energy state-independent antagonism between insulin
and AMPK was con¢rmed in hearts submitted to a 10 min
episode of anoxia (Fig. 2). Under these conditions, the inhi-
bition of AMPK activation by insulin (50%) was slightly larg-
er than in ischemia (Fig. 2A). In anoxia, like in ischemia,
insulin did not change the AMP/ATP ratio (Fig. 2B). In
agreement with previous studies [14], we also observed a small
but signi¢cant e¡ect of insulin on AMPK activity in normoxic
hearts.
Insulin did not modify AMPK activity when it was added
5 min after the beginning of anoxia, i.e. when AMPK was
already activated (Fig. 3). The lack of insulin e¡ect was con-
¢rmed for durations of anoxia (Fig. 3A) or insulin exposure
(Fig. 3B) that were the same as in Fig. 2, when insulin was
added before anoxia.
To know whether the insulin-induced mechanism could be
mediated by changes in the phosphorylation state of AMPK,
we resorted to immunoblots using an antibody raised against
a peptide corresponding to the amino acid sequence surround-
ing the phosphorylated Thr172 in AMPK. A 10 min episode
of ischemia or anoxia increased Thr172 phosphorylation of
both isoforms of the catalytic subunit of AMPK (Fig. 4A).
Insulin antagonized this phenomenon, its e¡ect being more
important in anoxia than in ischemia, consistent with the
slight di¡erence in AMPK activity (compare Figs. 1A and
2A). The e¡ect of insulin was con¢rmed separately for each
isoform (Fig. 4B).
The anti-AMPK e¡ect of insulin during anoxia was com-
pletely inhibited in the presence of 0.3 WM wortmannin, a
known inhibitor of phosphatidylinositol-3-kinase (PI3K;
Fig. 5). This anti-AMPK e¡ect was una¡ected by 0.25 WM
rapamycin, an inhibitor of p70 ribosomal S6 kinase activation
(Fig. 5).
4. Discussion
This work shows that insulin inhibited the activation of
AMPK resulting from ischemia or anoxia. The inhibitory ef-
fect of insulin corresponded to a decreased phosphorylation
state of Thr172 in the activation loop of the catalytic subunit
of AMPK. This is the ¢rst experimental evidence that AMPK
activity can be modi¢ed without change in the total adenine
nucleotides concentration. In agreement with this ¢nding, per-
fusion of rat hearts with non-esteri¢ed fatty acids has recently
been found to activate AMPK without a¡ecting the AMP/
ATP ratio (E.D. Saggerson and H.S. Clark, personal commu-
nication). Moreover, in our ischemic models, insulin did not
a¡ect the PCr/Cr ratio, which is known to be sensitive to
small and rapid changes in the energy state of the cytosol
during an anaerobic episode. Insulin was also without e¡ect
on lactate accumulation and hence on glycolysis, which is al-
ready stimulated under these anaerobic conditions. This is in
Fig. 2. E¡ect of insulin pre-treatment on AMPK activity (A) and
AMP/ATP ratio (B) in rat hearts submitted to anoxia. A scheme of
the experimental protocol and the times of sampling are given at
the top of the ¢gure. After 15 min equilibration, the hearts were
perfused for 5 min with insulin (100 nM) before anoxia was started.
The hearts were freeze-clamped after 10 min anoxia. Open bars:
control hearts; closed bars: insulin pre-treated hearts. The values
are the means þ S.E.M. of at least four hearts. *P6 0.05 indicates
values that are statistically di¡erent from the corresponding non-in-
sulinic hearts.
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line with the previously reported lack of an additive e¡ect of
insulin and severe ischemia on glucose metabolism in the
heart [21,22]. Therefore, no change in the AMP/ATP ratio
is expected in the cytosolic compartment where glycolysis op-
erates.
The anti-AMPK e¡ect of insulin was only observed when
insulin was given before the anaerobic episode. Moreover, we
previously demonstrated that ischemia inhibits insulin signal-
ing [23]. Therefore, both observations suggest that the e¡ect
of insulin on the AMPK cascade was initiated in normoxic
hearts before the anaerobic episode. This priming of the
hearts by insulin pre-treatment prevented the phosphorylation
and activation of AMPK brought about by ischemia or an-
oxia.
The decreased phosphorylation state of Thr172 could result
either from an inactivation of AMPKK, from the phosphor-
ylation of AMPK on a site that prevents Thr172 phosphory-
lation, or, alternatively, from the activation of a phosphatase.
However, the latter is considered to be unlikely, because it is
not consistent with the fact that insulin action should precede
the anaerobic AMPK activation. Whatever the mechanism
involved, insulin action could result in a decreased sensitivity
of the AMPK/AMPKK system towards changes in adenine
nucleotide concentration.
Fig. 3. AMPK activity in anoxic hearts treated with insulin after the beginning of anoxia. A scheme of the experimental protocol and the times
of sampling are given at the top of the ¢gure. After 15 min equilibration, the hearts were submitted to anoxia. Insulin (100 nM) was added
5 min after the beginning of anoxia. The hearts were freeze-clamped after 10 min (A) or 20 min (B) anoxia. Open bars: control hearts; closed
bars: insulin pre-treated hearts. The values are the means þ S.E.M. of at least four hearts. *P6 0.05 indicates values that are statistically di¡er-
ent from the corresponding non-insulinic hearts.
Fig. 4. E¡ect of insulin pre-treatment on the phosphorylation state of Thr172 after 10 min ischemia or anoxia. A: The catalytic subunits (K1
and K2) were co-immunoprecipitated (IP: anti-K1K2AMPK). B: The catalytic subunits were immunoprecipitated separately (IP: anti-K1AMPK
or anti-K2AMPK). The amounts of heart extract used for the immunoprecipitation are indicated. The phosphorylation state was compared by
immunoblots with anti-phosphoThr172 AMPK antibody (IB: anti-pThr172AMPK). The amount of AMPK present in the extract was the same
as measured by immunoblots with anti-K2AMPK (not shown). The blots shown are representative of three di¡erent experiments.
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The anti-AMPK e¡ect of insulin was wortmannin-sensitive,
like most short-term e¡ects of insulin, suggesting that it is
mediated by PI3K. According to our current understanding
of insulin action, a cross-talk between the AMPK cascade and
a step of the insulin signaling pathway located downstream of
PI3K has not been reported and is certainly worth investigat-
ing.
AMPK activity decreased between 10 and 20 min ischemia,
although the AMP/ATP ratio still increased about 10-fold.
This may be related to a progressive decrease in the concen-
tration of ATP, which is a substrate for AMPKK. Moreover,
it is likely that the large increase in AMP competes with the
small amount of ATP remaining, and so inhibits phosphory-
lation of AMPK by AMPKK. The transient activation of
AMPK could also re£ect the occurrence of a negative feed-
back mechanism.
The e¡ect of insulin was readily observed under anaerobic
conditions, when AMPK activity is already elevated. It was
less evident under normoxic conditions, although it has been
originally reported for such conditions [14]. In normoxic con-
ditions, the metabolic consequences of the interaction between
insulin and AMPK would be to increase malonyl-CoA con-
centrations. This would eventually limit fatty acid oxidation
and is in line with the observation that insulin favors glucose
utilization and restricts fatty acid oxidation. The absence of
oxygen should re-inforce this e¡ect of insulin to inhibit fatty
acid oxidation. Under the same conditions, although insulin
inhibits AMPK, the stimulation of glycolysis should remain
elevated, because both ischemia and insulin stimulate glycol-
ysis by activating the same key steps [7,9,21], namely the re-
cruitment of GLUT4 and the activation of 6-phosphofructo-
2-kinase. Therefore, we speculate that the physiological rele-
vance of insulin counteracting AMPK activation in ischemic
hearts concerns other targets of this kinase, as yet unknown.
It is also worth considering whether this anti-AMPK e¡ect is
related to the protective role of insulin against ischemia-reper-
fusion injuries in the heart.
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Fig. 5. E¡ect of wortmannin and rapamycin on the insulin-induced
inhibition of AMPK activation after 10 min of anoxia. A scheme of
the experimental protocol and the time of sampling are given at the
top of the ¢gure. The values are the means þ S.E.M. of at least six
hearts. *P6 0.05 indicates values that are statistically di¡erent from
the corresponding non-insulinic hearts.
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